Sun Pharma successfully removed an injunction in the US on the launch of its Leqselvi for alopecia areata, a common form of hair loss, that was sought by rival Incyte. The decision in the US Court ...

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma’s sales in the financial year 2026 (FY26), and $125 million in FY27. Sun Pharma said it will disclose ...

A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata. In a brief filing with the National Stock Exchange (NSE ...

Stay updated with the latest news on Times of India. Get all the trending City News, India News, Business News, and Sports ...

The US Appeal Court gave a favorable ruling on Indian drugmaker Sun pharmaceuticals’ alopecia drug Leqselvi. Also of note, the US Food and Drug Administration (FDA) last week approved Bristol Meyers ...

Sun Pharmaceutical Industries, has clawed back nearly half of those losses. Recent acquisitions, a favourable court ruling in the case of the hair loss drug Leqselvi, an edge over peers owing to its ...

Sun Pharmaceutical Industries Ltd announced that a US court has ruled in its favour, immediately vacating a preliminary injunction that restricted the launch of LEQSELVI, a drug for treating ...